샘플 요청 목록

 카트 문의
시장보고서
상품코드
1796033

세계의 표적 치료제 시장

Targeted Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 382 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

표적 치료제 세계 시장은 2030년까지 1,118억 달러에 달할 전망

2024년에 805억 달러로 추정되는 표적 치료제 세계 시장은 2024년부터 2030년까지 CAGR 5.6%로 성장하여 2030년에는 1,118억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단클론항체는 CAGR 6.7%를 기록하며 분석 기간 종료시에는 739억 달러에 달할 것으로 예상됩니다. 저분자 부문의 성장률은 분석 기간 동안 CAGR 3.7%로 추정됩니다.

미국 시장은 219억 달러로 추정, 중국은 CAGR 9.1%로 성장할 것으로 예측

미국의 표적 치료제 시장은 2024년에 219억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 228억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.7%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 표적 치료제 시장 - 주요 동향과 촉진요인 정리

표적 치료제의 획기적인 발전 요인은?

표적 치료제는 질병 세포에서 특이적으로 발현되거나 변화하는 분자 또는 경로와 특이적으로 상호작용하도록 설계되어 표적 외 영향을 최소화하는 치료법을 말합니다. 여기에는 단클론항체, 저분자 억제제, 항체약물접합체(ADC), 선택적 프로모터가 있는 유전자 치료 벡터, RNA 치료제 및 펩타이드 백신과 같은 새로운 치료법이 포함됩니다. 정밀의학 이니셔티브, 멀티오믹스 프로파일링, 컴패니언 다이애그노스틱스(Companion Diagnostics)는 특정 환자군에 맞춤화된 신약 개발 파이프라인을 지원합니다. 제약사들은 드라이버 돌연변이(EGFR, ALK, BRAF 등), 후생유전학적 조절인자, 면역체크포인트를 타겟으로 한 선택성이 높은 화합물을 개발하고 있습니다. 제조의 복잡성과 규제는 여전히 높지만, 확장 가능한 모듈식 플랫폼과 적응형 임상시험 설계로 인해 시장 출시 시간이 단축되고 있습니다.

혁신이 표적 약물의 한계를 뛰어넘는 곳은 어디일까?

혁신적인 분야 중 하나는 종양 항원과 면역 이펙터를 동시에 결합할 수 있는 이중특이성항체입니다. 겸상 적혈구증과 같은 체세포 돌연변이를 표적으로 하는 CRISPR 기반 유전자 편집 치료는 mRNA 지질 나노입자 플랫폼을 통해 조직 특이적 전달이 가능해지면서 치료적 접근법으로 각광받고 있습니다. 액체 생검, 디지털 방울 PCR, 단일 세포 RNA-seq 등 진단의 진화를 통해 실시간 모니터링과 적응형 투여 계획이 가능해졌습니다. AI를 통한 표적 예측을 이용한 계산적 약물 설계는 신약 개발의 타임라인을 단축하고 있습니다. 약리유전체학을 전자의무기록에 통합하여 실용적인 처방을 촉진하고 값비싼 부작용을 피하는 데 도움을 주고 있습니다.

최종사용자의 요구는 어떻게 치료 전략을 형성하고 있는가?

암 전문의들은 내성을 극복하고 치료 성적을 개선하기 위해 표적 치료제와 면역치료의 병용요법을 선호하지만, 이를 위해서는 약물 간 상호작용과 바이오마커에 기반한 치료를 신중하게 고려해야 합니다. 희귀질환 커뮤니티는 초희귀 표적 치료제에 대한 수요를 촉진하고, 규제 당국이 희귀질환 치료제의 신속한 승인과 희귀질환 치료제 개발을 장려하도록 촉구하고 있습니다. 피하 ADC, 자가주사 가능한 키나아제 억제제, 디지털 애드히어런스 시스템 등 환자 중심의 투약 방법이 확산되고 있습니다. 시판 후 실제 임상 데이터를 통한 근거 창출이 지불 측의 수용성을 더욱 형성하고, 제약사들은 가치 기반 계약과 결과 등록에 대한 투자를 요구받게 될 것입니다. 신흥 시장에서는 단계적 가격 책정과 지역 진단 연구소를 채택하여 표적 의약품에 대한 접근성 격차를 해소하고 있습니다.

표적 치료제 급증의 요인은?

표적 치료제 시장의 성장은 종양 및 유전성 질환의 부담 증가, 바이오마커 기반 임상 경로의 광범위한 채택, 첨단 약물전달 플랫폼의 통합 등 여러 요인에 의해 주도되고 있습니다. 확장 가능한 RNA와 세포 치료제 생산이 등장하면서 바이오제약은 저분자에서 생물학적 제제까지 모든 형태의 투자를 하게 되었습니다. 규제 당국은 조기 승인, 적응증 허가, 동반진단 프레임워크를 강화하고 있습니다. 의료 서비스 제공자는 정확성을 우선시하는 프로토콜을 선택하고, 지불자는 바이오마커의 존재와 임상적 유용성을 핵심으로 하는 가치 기반 상환을 받아들이고 있습니다. 팬데믹 시대에 mRNA 기술의 발전과 플랫폼의 적응성이 여러 치료 분야에 걸친 파이프라인의 확장을 더욱 촉진할 것입니다.

부문

유형(단클론항체, 저분자), 용도(유방암 용도, 대장암 용도, 백혈병 용도, 폐암 용도, 림프종 용도, 다발성 경화증 용도, 신장암 용도, 습윤형 노인황반변성 용도, 기타 용도), 판매 채널(병원 약국, 소매 약국, 온라인 판매 채널)

조사 대상 기업 사례

  • AbbVie
  • Amgen
  • AstraZeneca plc
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision NanoSystems Inc.
  • Roche Holdings AG
  • Sanofi
  • Seagen Inc.
  • Takeda Pharmaceutical Company
  • Zymeworks Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.02

Global Targeted Therapeutics Market to Reach US$111.8 Billion by 2030

The global market for Targeted Therapeutics estimated at US$80.5 Billion in the year 2024, is expected to reach US$111.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$73.9 Billion by the end of the analysis period. Growth in the Small Molecule segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$21.9 Billion While China is Forecast to Grow at 9.1% CAGR

The Targeted Therapeutics market in the U.S. is estimated at US$21.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.8 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Targeted Therapeutics Market - Key Trends & Drivers Summarized

What Makes Targeted Therapeutics a Breakthrough?

Targeted therapeutics refers to treatments designed to specifically interact with molecules or pathways that are uniquely expressed or altered in disease cells, minimizing off-target effects. This includes monoclonal antibodies, small-molecule inhibitors, antibody-drug conjugates (ADCs), gene therapy vectors with selective promoters, and emerging modalities like RNA therapeutics and peptide vaccines. Precision medicine initiatives, multi-omics profiling, and companion diagnostics support drug-development pipelines tailored to specific patient subpopulations. Pharmaceutical companies are developing ever more selective compounds targeting driver mutations (e.g., EGFR, ALK, BRAF), epigenetic regulators, and immune checkpoints. Manufacturing complexity and regulatory rigor remain high, but scalable modular platforms and adaptive clinical trial designs have reduced time-to-market.

Where Is Innovation Pushing the Envelope in Targeted Drugs?

One transformative area is bispecific antibodies that can simultaneously bind tumor antigens and immune effectors; next-generation ADCs carry dual payloads for synergistic cytotoxicity. CRISPR-based gene-editing therapies targeting somatic mutations (e.g., sickle-cell disease) are awaking as curative approaches, with mRNA lipid-nanoparticle platforms enabling tissue-specific delivery. Diagnostic evolution-liquid biopsies, digital droplet PCR, single-cell RNA-seq-is enabling real-time monitoring and adaptive dosing schemes. Computational drug-design using AI-driven target prediction is compressing discovery timelines. Integration of pharmacogenomics in electronic health records is facilitating actionable prescribing and helping avoid costly side effects.

How Are End-User Needs Shaping Therapeutic Strategies?

Oncologists favor combination regimens of targeted agents with immunotherapies to overcome resistance and improve outcomes, necessitating careful consideration of drug-drug interactions and biomarker-guided treatment. Rare-disease communities drive demand for ultra-rare targeted therapies, pushing regulatory agencies to fast-track approvals and incentivize orphan drug development. Patient-centric administration methods, like subcutaneous ADCs, home-injectable kinase inhibitors, and digital adherence systems, are gaining traction. Evidence generation through post-marketing real-world data further shapes payer acceptance, requiring drug developers to invest in value-based contracts and outcome registries. Emerging markets adopt tiered pricing and regional diagnostic labs to bridge access gaps for targeted drugs.

What’s Catalyzing the Surge in Targeted Therapeutics?

The growth in the targeted therapeutics market is driven by several factors such as the rising burden of oncology and genetic disorders, widespread adoption of biomarker-driven clinical pathways, and integration of advanced drug-delivery platforms. The emergence of scalable RNA and cell therapy manufacturing has generated biopharma investment across modalities-from small molecules to biologics. Regulatory agencies are enhancing frameworks for accelerated approvals, adaptive licensing, and companion diagnostics. Healthcare providers increasingly opt for precision-first protocols, while payers are embracing value-based reimbursements keyed to biomarker presence and clinical benefit. Pandemic-era advances in mRNA tech and platform adaptability further catalyze pipeline expansion across multiple therapeutic areas.

SCOPE OF STUDY:

The report analyzes the Targeted Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monoclonal Antibodies, Small Molecule); Application (Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application, Renal Cancer Application, Wet Age-Related Macular Degeneration Application, Other Applications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie
  • Amgen
  • AstraZeneca plc
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision NanoSystems Inc.
  • Roche Holdings AG
  • Sanofi
  • Seagen Inc.
  • Takeda Pharmaceutical Company
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Targeted Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Precision Medicine Throws the Spotlight on Targeted Therapeutic Modalities
    • Expansion of Biomarker Discovery and Companion Diagnostics Strengthens Business Case for Targeted Drug Development
    • Growth in Oncology Pipeline Propels Demand for Tumor-Specific Targeted Treatment Platforms
    • Advancements in Monoclonal Antibodies and Antibody-Drug Conjugates Drive Innovation in Targeted Therapy
    • Integration of Genomics and AI-Driven Drug Design Enhances Precision and Efficacy of Therapies
    • High Investment in Immunotherapy and CAR-T Technologies Expands Pipeline of Targeted Immuno-Oncology Products
    • Increased Clinical Trial Success Rates for Targeted Agents Boost Stakeholder Confidence
    • Shift Toward First-Line Use of Targeted Drugs in High-Burden Diseases Sustains Market Growth
    • Rising Demand for Less Toxic Alternatives to Chemotherapy Spurs Interest in Targeted Delivery
    • Expansion of Cell and Gene Therapy Ecosystems Creates Convergence Opportunities with Targeted Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Targeted Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Wet Age-Related Macular Degeneration Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Wet Age-Related Macular Degeneration Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Wet Age-Related Macular Degeneration Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Colorectal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Colorectal Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Leukemia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Multiple Sclerosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Multiple Sclerosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Multiple Sclerosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Renal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Renal Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Renal Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Targeted Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Targeted Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Targeted Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Targeted Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Targeted Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Targeted Therapeutics by Type - Monoclonal Antibodies and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Targeted Therapeutics by Type - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Small Molecule for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Targeted Therapeutics by Application - Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Targeted Therapeutics by Application - Percentage Breakdown of Value Sales for Wet Age-Related Macular Degeneration Application, Other Applications, Breast Cancer Application, Colorectal Cancer Application, Leukemia Application, Lung Cancer Application, Lymphoma Application, Multiple Sclerosis Application and Renal Cancer Application for the Years 2014, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Targeted Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Targeted Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제